Cspc Zhongnuo Pharmaceutical (shijiazhuang) Co., Ltd.

This Phase 2 trial tests an injection called SYH2070 in 18 Chinese adults with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition causing extremely high cholesterol. Participants receive the drug for 48 weeks to see if it safely lowers their LDL cholesterol…

This phase 2 trial tests an investigational injection called SYH2070 in adults with mixed hyperlipidemia—a condition where both cholesterol and triglycerides are high. Participants must already be on stable statin therapy. The study compares three doses of SYH2070 against a place…

This Phase 3 trial tests an injection called SYH2053 for people with heterozygous familial hypercholesterolemia (HeFH), a genetic condition causing very high LDL cholesterol. About 135 adults on stable statin therapy will receive either the drug or a placebo. The main goal is to …

This Phase 3 trial tests a new injectable drug called SYH2053 in 760 adults with high cholesterol or mixed lipid disorders. Participants receive either the drug or a placebo to see if it safely lowers LDL ('bad') cholesterol. The study aims to offer a new treatment option for peo…

This study tests whether a new generic version of a 3-month schizophrenia injection works the same as the brand-name drug Invega Trinza. About 260 Chinese adults with stable schizophrenia will receive multiple doses of either the test or reference drug. The goal is to see if the …

This phase 1 trial is testing a new injection called SYH2070 in 48 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure blood fat levels. This is an ear…

This early-stage trial is testing a new drug called SYH2061 in 40 healthy adults aged 18 to 55. The main goal is to see if it is safe and how the body handles it. Participants receive either the drug or a placebo by injection, and researchers monitor for side effects and measure …